The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report

The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report

Siponimod (Kajendra) is a sphingosine-1-phosphate receptor modulator type 1 and 5 (S1P1,5), the first targeted agent for the treatment of patients with secondary progressive multiple sclerosis, both with and without exacerbations and/or activity according to magnetic resonance imaging. The drug was...

Full description

Bibliographic Details
Main Authors:	Denis S. Korobko, Ivan Ie. Arkhipov, Anna I. Prokaeva, Ekaterina V. Tret'iakova
Format:	Article
Language:	Russian
Published:	ZAO "Consilium Medicum" 2023-05-01
Series:	Consilium Medicum
Subjects:	siponimod secondary progressive multiple sclerosis clinical case
Online Access:	https://consilium.orscience.ru/2075-1753/article/viewFile/553315/132684

Similar Items

New possibilities for the therapy of secondary progressive multiple sclerosis
by: A. M. Petrov, et al.
Published: (2019-12-01)

New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis
by: D. S. Kasatkin, et al.
Published: (2021-02-01)

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
by: Liesa Regner-Nelke, et al.
Published: (2022-11-01)

Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
by: Newshan Behrangi, et al.
Published: (2019-01-01)

Disease Reactivation in Secondary Progressive Multiple Sclerosis Patients Switching from Fingolimod to Siponimod: A Case Series
by: Gianmarco Abbadessa, et al.
Published: (2022-10-01)

Macular edema after siponimod treatment for multiple sclerosis: a case report and literature review
by: Qingsheng Li, et al.
Published: (2023-07-01)

Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review
by: Vincenzo Carlomagno, et al.
Published: (2023-07-01)

Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
by: Marc Bigaud, et al.
Published: (2023-05-01)

Comparison of medical and social characteristics and quality of life of patients with primary- and secondary-progressive multiple sclerosis
by: Ya. V. Vlasov, et al.
Published: (2021-09-01)

Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects»
by: N. V. Khachanova, et al.
Published: (2019-12-01)

Systematic literature review and meta-analysis of the prevalence of secondary progressive multiple sclerosis in the USA, Europe, Canada, Australia, and Brazil
by: Vijayalakshmi Vasanthaprasad, et al.
Published: (2022-08-01)

Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype
by: Bruno Brochet, et al.
Published: (2022-01-01)

Consensus on early detection of disease progression in patients with multiple sclerosis
by: José E. Meca-Lallana, et al.
Published: (2022-07-01)

Multiple sclerosis: modern diagnostic markers and prognostic factors of disease progression
by: A. I. Prokaeva, et al.
Published: (2024-03-01)

Bioavailable central nervous system disease-modifying therapies for multiple sclerosis
by: Hans-Peter Hartung, et al.
Published: (2023-11-01)

The Need for the Closer Monitoring of Novel Drugs in MS: A Siponimod Retrospective Cohort Study (Realhes Study)
by: Arantxa Sancho-López, et al.
Published: (2023-10-01)

Comparing power and activity of lower body muscles in two types of multiple sclerosis patients and healthy individuals
by: Talebi V, et al.
Published: (2020-05-01)

Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021
by: Crystal Watson, et al.
Published: (2023-09-01)

Changes in retinal structures as markers of multiple sclerosis progression
by: M. O. Poplyak, et al.
Published: (2021-12-01)

Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis
by: Saeideh Salehizadeh, et al.
Published: (2022-06-01)

Editorial: Measuring progression in Multiple Sclerosis: Progressing beyond the ordinary
by: Carynn Koch, et al.
Published: (2022-11-01)

Does Siponimod Exert Direct Effects in the Central Nervous System?
by: Markus Kipp
Published: (2020-07-01)

Long-Term Disability Outcomes in Relapsing–Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression
by: Laura Barcutean, et al.
Published: (2024-03-01)

The Factors Associated With Olfactory Dysfunction in Patients with Multiple Sclerosis
by: Mostafa Almasi, et al.
Published: (2021-01-01)

Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis
by: Smaranda Maier, et al.
Published: (2023-02-01)

Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing–Remitting from Secondary Progressive Multiple Sclerosis. A Review
by: Sylwia Pietrasik, et al.
Published: (2021-11-01)

Advances in clinical diagnosis of secondary progressive multiple sclerosis
by: ZHANG Chao, GAO Xue
Published: (2022-12-01)

Mitoxantrone in the treatment of multiple sclerosis: a single-center experience
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-06-01)

Monoclonal antibodies in the treatment of multiple sclerosis: from clinical research to practical application
by: N. Yu. Lashch
Published: (2020-07-01)

Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives
by: Gary Álvarez Bravo, et al.
Published: (2022-06-01)

In Silico Analysis Highlights Potential Predictive Indicators Associated with Secondary Progressive Multiple Sclerosis
by: Marco Calabrò, et al.
Published: (2024-03-01)

Linear Modeling of Multiple Sclerosis and Its Subgroubs
by: Yeliz Karaca, et al.
Published: (2015-03-01)

Migraine, interferon β1a and siponimod immunomodulator therapies
by: Ashraf A. Dahaba, et al.
Published: (2022-04-01)

COVID-19 and multiple sclerosis: is there a connection?
by: I. E. Arkhipov, et al.
Published: (2024-03-01)

Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis
by: Carmen Alcalá Vicente, et al.
Published: (2022-10-01)

Clinical Outcome and Volumetric MRI Assessment of Brain and Cervical Spinal Cord Area in Secondary Progressive Multiple Sclerosis Patients Treated with Rituximab: one-year follow-up (ORP-08)
by: Yousef Mokary, et al.
Published: (2023-11-01)

Symptom-Level Disability Status Assessed with an Electronic Unsupervised Patient-Reported Expanded Disability Status Scale (ePR-EDSS) in Multiple Sclerosis Patients—The Example of Croatia
by: Ana Jerković, et al.
Published: (2022-07-01)

Neurodegeneration and its potential markers in the diagnosing of secondary progressive multiple sclerosis. A review
by: Aleksandra Pogoda-Wesołowska, et al.
Published: (2023-09-01)

Clinical markers for unfavorable course of multiple sclerosis
by: Mariya S. Matrosova, et al.
Published: (2023-09-01)

Effect of disease duration on personality type in multiple sclerosis patients and healthy individual
by: Sahar Vesal, et al.
Published: (2016-01-01)